Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y mAbs Therapeutics : HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $68 From $70, Maintains Buy Rating

06/28/2021 | 07:12am EST


ę MT Newswires 2021
All news about Y-MABS THERAPEUTICS, INC.
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 66,7 M - -
Net income 2021 -49,0 M - -
Net cash 2021 85,0 M - -
P/E ratio 2021 -10,0x
Yield 2021 -
Capitalization 480 M 480 M -
EV / Sales 2021 5,92x
EV / Sales 2022 1,32x
Nbr of Employees 125
Free-Float -
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 10,99 $
Average target price 43,40 $
Spread / Average Target 295%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Director, Chief Executive & Commercial Officer
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-32.20%480
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-9.18%51 206
BIONTECH SE-39.28%37 805